---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-009692"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:41:52.392676+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# uniQure reports Q2 loss of $37.7M; FDA agrees on AMT-130 BLA pathway for Q1 2026 submission

## Summary
- Revenue $5.3M, down from $11.1M YoY; net loss $37.7M ($0.69/share).
- FDA alignment on SAP and CMC for AMT-130 BLA; topline three-year data in Sept 2025.
- AMT-260 first patient showed 92% seizure reduction at 5 months with no serious AEs.
- Cash $377M expected to fund operations into H2 2027.
- Appointed Kylie O’Keefe as Chief Customer and Strategy Officer.

## SEC filing metadata
- accession: 0001558370-25-009692
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/0001558370-25-009692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/qure-20250729x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-009692
- JSON: https://secwatch.observer/filing/0001558370-25-009692.json
- Plain text: https://secwatch.observer/filing/0001558370-25-009692.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.